Synopsis
- The pharmaceutical industry is set to face new challenges such as inflation in a post-COVID-19 world.
- Genomics, RWE, and IO will dominate as the most impactful trends in the biopharmaceutical industry next year.
- Among the most impactful trends, genomics will be the key focus in 2023.
- Inflation and drug pricing pressures will be the top hindrances for pharmaceutical sector growth.
- Vertical integration, patent expiry of biologics, mega M&As, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry.
- Big data and AI will continue to dominate as transformational forces in the healthcare sector in 2023.
- Across the entire value chain, supply chains and manufacturing will be impacted the most by inflation in 2023.
- The biopharmaceutical industry is less optimistic about industry growth in the next 12 months compared to previous years.
- The pharmaceutical industry will continue to pursue its efforts to become more sustainable, with more companies committing to ESG strategies.
- Oncology, CNS, and infectious diseases will be the dominant areas for clinical trials initiated in 2023.
- Despite political rhetoric, COVID-19-induced pharmaceutical onshoring may not happen.
- While already met with skepticism by pharma, the Inflation Reduction Act will have to show if it can live up to its name.
Key Highlights
- In 2023, economies and industries will continue to deal with inflationary pressures.
- Inflation will disrupt pharmaceutical manufacturing and supply chains.
- Genomics is the trend that will continue to have the greatest impact on the pharmaceutical industry in 2023.
- Inflation together with drug pricing and reimbursement-related concerns will be the leading impediment to industry growth.
- Vertical integration, patent expiry of biologics, mega M&As, and ESG factors will have the most positive impacts on industry.
- While less than in previous years, the biopharmaceutical industry is still optimistic about its growth in 2023.
Scope
- Benchmark the impact of major themes on the biopharmaceutical industry in 2023, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends.
- Identify themes that will have the greatest positive or negative impact in 2023.
- Capture opinions on these themes from industry respondents.
- Assess the impact of COVID-19 on the biopharmaceutical sector.
- Explore how inflation will affect the pharmaceutical industry in 2023.
Reasons to Buy
- Stay up to date with the major emerging technologies, regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2023.
- Explore how the biopharmaceutical landscape has changed.
- Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023.
- Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry.
- Identify emerging industry trends and innovations to gain a competitive advantage.
Table of Contents
1. Executive Summary
2. Study Design
3. Emerging Industry Trends
4. Emerging Regulatory and Macroeconomic Trends
5. Emerging Technologies
6. Industry Growth Prospects
7. Watch Outs
8. Summary of Key Findings
9. Appendix
10. Contact the Publisher
List of Tables
Table 1: Personalized medicine drugs expected to launch in 2023 for oncology indications
Table 2: 12 drugs in pre-registration stage expected be approved by the end of 2022 and 2028 sales forecast
List of Figures
Figure 1: Respondent mix - geography
Figure 2a: Respondent mix - seniority level
Figure 2b: Respondent mix - company size
Figure 3: Respondent mix - headquarter locations
Figure 4: Top emerging pharmaceutical industry trend for 2023
Figure 5: Top emerging pharmaceutical industry trend 2023 vs 2022
Figure 6: Most impactful industry trends by region I
Figure 7: Most impactful industry trends by region II
Figure 8: Industry trends with the greatest impact on pharmaceutical industry in 2023
Figure 9a: Number of trials initiated by phase of development, 2018-2022
Figure 9b: Number of trials initiated by sponsor type, 2018-2022
Figure 10a: Number of mRNA vaccine clinical trials by phase of development 2022
Figure 10b: Number of mRNA vaccine clinical trials by sponsor type 2022
Figure 11: Number of RWE trials by sponsor type and year
Figure 12a: Number of ICI indications by phases of development
Figure 12b: Number of CART-T indications by phases of development
Figure 13: How companies addressed clinical trial disruptions due to COVID-19 pandemic 2020-2022
Figure 14: Company usage of DCT before COVID-19
Figure 15: Percentage of clinical trials using DCT components
Figure 16: Main benefits associated with using DTx
Figure 17a: Microbiome agents in development in each therapy area
Figure 17b: Percent microbiome agents in development for each indication - Infectious disease
Figure 17c: Percent microbiome agents in development for each indication - gastrointestinal
Figure 17d: Number of clinical trials initiated per year with microbiome-targeting therapeutics
Figure 18: Regenerative medicine market 2021-2028
Figure 19: Biggest barrier associated with a wider implementation of electronic healthcare records
Figure 20: Regulatory and macroeconomic trends with the greatest positive and negative impact on pharmaceutical industry in 2023
Figure 21: Impact of emerging regulatory and macroeconomic trends on pharmaceutical industry in 2023
Figure 22: Change in average drug price 2017-2021
Figure 23: Usage of IRP
Figure 24a: Rise of pharmaceutical prices in 2023
Figure 24b: Rise of pharmaceutical prices in 2023 by region
Figure 25: Factors driving government endorsement of real-terms drug price increases
Figure 26a: Rheumatoid arthritis: biosimilar sales forecast, 7MM and Australia, 2019-2029
Figure 26b: Rheumatoid arthritis: average biosimilar prescription, 7MM and Australia, 2019-2029
Figure 27: Number of clinical trials by year
Figure 28: Impact of emerging regulatory and macroeconomic trends on pharmaceutical industry in 2023
Figure 29: Top positive emerging regulatory and macroeconomic trends - highest positive scores by geography
Figure 30: Top positive emerging regulatory and macroeconomic trends - high positive vs low negative scores
Figure 31: Impact of emerging technologies on pharmaceutical industry in 2023
Figure 32: Impact of emerging technologies on pharmaceutical industry in 2020-2023
Figure 33: Impact on investment in emerging technologies by COVID-19 outbreak
Figure 34: Impact on investment in emerging technologies by inflation and rising costs during next 12 months
Figure 35: Emerging technologies with the greatest impact on pharmaceutical industry in 2023
Figure 36: Top five emerging technologies 2020-2023
Figure 37: Job analytic on AI and big data
Figure 38: Factors hinder digital transformation at organizations
Figure 39: Sentiment on industry’s growth during next 12 months
Figure 40: Sentiment on industry’s growth during next 12 months, 2020-2023
Figure 41: Inflation impact on pharmaceutical value chain
Figure 42: Inflation impact on pharmaceutical value chain by region
Figure 43a: Deflation outlook
Figure 43b: Deflation outlook by region
Figure 44: Economic outlook of major markets
Figure 45a: HCPs’ opinions on whether the number of patients stopping or postponing treatments has increased
Figure 45b: Initiatives that could help to reduce inflation in the healthcare
Figure 46: HCPs’ thoughts on IRA’s ability to reduce drug prices
Figure 47: If pharma industry is doing enough to be more environmentally sustainable 2022 vs 2021
Figure 48a: Planned clinical trials in 2023 by phase
Figure 48b: Top industry sponsors for planned clinical trials in 2023
Figure 49a: Top countries for planned clinical trials in 2023 by number and phase
Figure 49b: Drug types for planned clinical trials in 2023 by phase
Figure 50a: Top therapy areas for planned clinical trials to be initiated in 2023
Figure 50b: Top indications for planned clinical trials to be initiated in 2023
Figure 51a: Projected trial completion in 2023 by phase
Figure 51b: Top industry sponsors for trials projected to be completed in 2023
Figure 52: Top 10 prescription drugs - 2022 vs 2023
Figure 53: Top 10 therapy areas - 2022 vs 2023
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Acceleron Pharma
- Atara Biotherapeutics
- Beta Pharma
- BioMarin Pharmaceutical
- BioNTech
- Bio-Thera Solutions
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Catalent
- Celerity Pharmaceuticals
- Celltrion
- Coherus BioSciences
- CSL Behring
- CStone Pharmaceuticals
- CVS Health Corp
- EirGenix
- Eli Lilly
- Exelead
- Exscientia
- Ferring Pharmaceuticals
- Fuji Pharma
- GSK
- Immunocore
- Insud Pharma
- InventisBio
- Johnson & Johnson
- Johnson Matthey
- Legend Biotech
- Loxo Oncology
- Medicaid Health Plans of America
- Merck
- Merck & Co
- Metrics Contract Services
- Midas Pharma
- Mirati Therapeutics
- National Institute for Health and Care Excellence
- Nippon Kayaku
- Novartis
- Ono Pharmaceutical
- Optum
- Organon
- OS Therapies
- PTC Therapeutics
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Sandoz
- Sarepta Therapeutics
- Shanghai Junshi Bioscience
- Sino Biopharmaceutical
- Stada Arzneimittel
- Stelis Biopharma
- Sumitomo Dainippon Pharma Oncology
- Teva Pharmaceutical Industries
- TRACON Pharmaceuticals
- UnitedHealth Group
- Veranova
- Xbrane Biopharma
